An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 12, 2003, Pages 1305-1315

  Rabe, Christian ^a   Lenz, Matthias ^a   Schmitz, Volker ^a   Pilz, Tillmann ^a   Fimmers, Rolf ^a   Sauerbruch, Tilman ^a   Caselmann, Wolfgang H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Carcinoma; Hepatitis B; Hepatitis C; Hepatocellular; Prognosis; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; EUROPE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 3943105433     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200312000-00009     Document Type: Article

References (43)

1. World Health Organization. World Health Report. Geneva: World Health Organization; 2000.
2. Blakely T, Bates M, Garrett N, Robson B. The incidence of hepatocellular carcinoma in New Zealand. N Z Med J 1998; 111:471-474.
3. Blakely TA, Bates MN, Baker MG, Tobias M. Hepatitis B carriage explains the excess rate of hepatocellular carcinoma for Maori, Pacific Island and Asian people compared to Europeans in New Zealand. Int J Epidemiol 1999; 28:204-210.
4. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al. High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology 1999; 46:357-359.
5. Kuper HE, Tzonou A, Kaklamani E, Hadziyannis S, Tasopoulos N, Lagiou P, et al. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control 2000; 11:171-175.
6. Zhang JY, Dai M, Wang X, Lu WQ, Li DS, Zhang MX, et al. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol 1998; 27:574-578.
7. Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer 1992; 69:2052-2054.
8. Peters M, Wellek S, Dienes HP, Junginger T, Meyer J, Meyer zum Buschendfelde KH, et al. Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C. Z Gastroenterol 1994; 32:146-151.
9. Petry W, Heintges T, Hensel F, Erhardt A, Wenning M, Niederau C, et al. Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic. Z Gastroenterol 1997; 35:1059-1067.
10. Kubicka S, Rudolph KL, Hanke M, Tietze MK, Tillmann HL, Trautwein C, et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20:312-318.
11. Hellerbrand C, Hartmann A, Richter G, Knoll A, Wiest R, Scholmerich J, et al. Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors. Dig Dis 2001; 19:345-351.
12. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36:909-915.
13. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160:3227-3230.
14. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 2000; 173:403-405.
15. Bethke BA, Schubert GE. Primary hepatic cancer and liver cirrhosis. Autopsy study covering fifty years. Hepatogastroenterology 1984; 31:211-214.
16. Rimkus K, Dhom G. The epidemiology of primary liver cancer in a West German population: the Saarland. J Cancer Res Clin Oncol 1986; 111:248-256.
17. Herold C, Reck T, Fischler P, Ott R, Radespiel-Troeger M, Ganslmayer M, et al. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 2002; 22:23-28.
18. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751-755.
19. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 2000; 31:840-845.
20. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89:2266-2273.
21. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31:133-141.
22. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001; 48:103-109.
23. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338.
24. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, et al. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001; 7:208-215.
25. Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998; 26:200-203.
26. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000; 95:218-222.
27. Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, et al. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 2002; 40:395-400.
28. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36:687-691.
29. Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, Vafiades I, et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002; 9:903-907.
30. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Markidou S, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002; 49:1245-1250.
31. Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 2001; 32:383-389.
32. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
33. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
34. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54.
35. Calvet X, Bruix J, Bru C, Gines P, Vilana R, Sole M, et al. Natural history of hepatocellular carcinoma in Spain. Five years' experience in 249 cases. J Hepatol 1990; 10:311-317.
36. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32:233-238.
37. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918-928.
38. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77:2217-2222.
39. Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 1988; 48:7314-7318.
40. Attali P, Prod'Homme S, Pelletier G, Papoz L, Ink O, Buffet C, et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 1987; 59:2108-2111.
41. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50:881-885.
42. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34:529-534.
43. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94:1760-1769.